NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
DiaMonTech announces price range for IPO
- DiaMonTech shares to be offered within price range of 32.00 euros to 38.00 euros per share
- Medical technology company with method for non-invasive blood glucose measurement expects issue volume of up to 68 million euros, assuming full exercise of the over-allotment option (“greenshoe option”)
- Offering of up to 1,796,875 shares consisting of 1,562,500 new shares from a capital increase and up to 234,375 shares pursuant to a greenshoe option
- Proceeds from the IPO shall be invested in particular in the further product development, the start of serial production as well as marketing and sales
- Offer period expected to run from 14 November to 26 November 2019
- Subscriptions can be made via the Xetra Tool “Direct Place” of the Frankfurt Stock Exchange from 14 November to 25 November 2019
- The first trading day on the regulated market (Prime Standard) of the Frankfurt Stock Exchange planned for 29 November 2019
Berlin, 13 November 2019 – Die DiaMonTech AG (“DiaMonTech” or the “Company”), a young medical technology company, has set the price range for its planned Initial Public Offering (IPO) on the Frankfurt Stock Exchange (Prime Standard) at 32.00 euros to 38.00 euros per share.
Thorsten Lubinski, CEO of DiaMonTech: “We operate in one of the most attractive growth markets with currently more than 400 million diabetics worldwide. With our portable “D-Pocket” we can for the first time provide them a precise non-invasive blood glucose measurement and thus make their life much easier. We are planning a market launch at the end of 2020. The proceeds from the IPO will enable us to accelerate our development and thus offer our products more quickly to a large number of diabetics. I am pleased that the subscription period for the new shares begins on 14 November which is World Diabetes Day.”
Expected issue volume of up to 68 million euros
The offering comprises a total of up to 1,796,875 shares and consists of two components:
1. Up to 1,562,500 newly issued ordinary shares from a capital increase against contributions in cash
2. Up to 234,375 ordinary shares, which will also be serviced within a potential over-allotment which is covered by a greenshoe option also from new shares
DiaMonTech AG and existing shareholders have agreed to a lock-up period of 12 months.
Assuming that all offered shares are placed and the greenshoe option is fully exercised, the issue volume would be in a range of 57.5 million euros and 68.3 million euros. This implies a total market capitalization (after inflow of the net proceeds) between around 216 million euros and around 255 million euros with a free float of around 26.7 percent.
The Company intends to invest the net proceeds in the planned growth and use the funds in particular for the further development of the “D-Pocket”, the start of serial production as well as marketing and sales.
The final offering price will be determined by means of a bookbuilding process and is expected to be set on 26 November 2019. The offer period begins on 14 November 2019 and ends on 25 November 2019 at 12:00 CET for private investors and on 26 November 2019 at 16:30 CET for institutional investors. The first day of trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange is planned for 29 November.
Subscription also via Direct Place of the Frankfurt Stock Exchange
Private investors in Germany can subscribe to the new DiaMonTech shares from 14 November 2019 via the Direct Place system of the Frankfurt Stock Exchange. Investors must submit an order for the shares with the stock exchange location “Frankfurt” via their bank or online broker, provided the bank or online broker is connected to Direct Place.
MainFirst Bank AG is acting as Sole Global Coordinator and Sole Bookrunner.
The securities prospectus will be available for download on the Company’s website www.diamontech.de/boersengang after approval by the German Federal Financial Supervisory Authority (BaFin).
DiaMonTech AG is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal detection technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.
More information about DiaMonTech can be found at www.DiaMonTech.de/home.
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
The information contained herein is not for distribution, directly or indirectly, in or into the United States of America (including its territories and possessions of any State of the United States of America or the District of Columbia) and must not be distributed to U.S. persons (as defined in Regulation S of the U.S. Securities Act of 1933, as amended (“Securities Act”)) or publications with a general circulation in the United States of America. This publication constitutes neither an offer to sell nor a solicitation to buy or subscribe to securities in the United States of America. Securities of DiaMonTech AG (the “Company”) have not been and will not be registered under the Securities Act and may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act. The Company does not intend to register any portion of the offering in the United States of America or to conduct a public offering of the securities in the United States of America.
This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. No offer of the securities of the Company is being, or will be made to the public outside the Federal Republic of Germany (“Germany”).
The offer in Germany will be made solely by means of, and on the basis of, a securities prospectus for the purposes of Regulation (EU) 2017/1129 as amended (the “Prospectus Directive”) to be approved by the German Federal Financial Supervisory Authority (BaFin). After the approval the securities prospectus will be available free of charge at the Company’s office, as well as, for viewing in electronic form, on the Company’s website https://www.diamontech.de/ipo. An investment decision regarding the publicly offered securities of the Company should only be made on the basis of the securities prospectus.
In member states of the European Economic Area (“EEA”) other than Federal Republic of Germany (“Germany”), this information is only addressed to and directed at persons who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Directive (“Qualified Investors”).
In the United Kingdom, this information is directed at and/or for distribution only to (i) investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,as amended (the “Order”), or (ii) high net worth companies falling within article 49(2)(a) to (d) of the Order (each such person hereinafter a “relevant person”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this information or any of its contents.
Statements contained herein may constitute “forward-looking statements.” Forward-looking statements are generally identifiable by the use of the words “may”, “will”, “should”, “plan”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “project”, “goal” or “target” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Company does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.
In connection with the placement of shares of DiaMonTech AG, MainFirst Bank Aktiengesellschaft will act as the stabilisation manager and may, as stabilisation manager, make over-allotments and take stabilisation measures in accordance with legal requirements (Art. 5(4) and (5) of the Market Abuse Regulation (EU) No. 596/2014 in conjunction with Articles 5 through 8 of the Commission Delegated Regulation (EU) 2016/1052) to support the market price of DiaMonTech AG’s shares and thereby counteract any selling pressure. The stabilisation manager is under no obligation to take any stabilisation measures. Therefore, stabilisation may not necessarily occur and may cease at any time. Such measures may be taken on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) from the date when trading in the shares of DiaMonTech AG is commenced on the regulated market segment (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) and must be terminated no later than 30 calendar days after this date (the “Stabilisation Period”). Stabilisation transactions aim at supporting the market price of DiaMonTech AG’s shares during the Stabilisation Period. These measures may result in the market price of DiaMonTech AG’s shares being higher than would otherwise have been the case. Moreover, the market price may temporarily be at an unsustainable level.
13.11.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de